Tetherex Pharmaceuticals Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tetherex Pharmaceuticals Corporation
April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2014.
France's Rhenovia Pharma will recruit talent in the U.S. and Europe and offer its biosimulation techniques for use in developing drugs that target CNS disease, a previously difficult area for computer modeling.
- Large Molecule
- Other Names / Subsidiaries
- Tetherex Pharmaceuticals, Inc.